drugset / Trial / NCT07522801
A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the benefit of a precision medicine based strategy (targeted therapeutic options (TTOs)) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) (in terms of composite remission).
Timeline
- Start
- 2026-09-01
- Primary completion
- 2029-12-01
- Completion
- 2030-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asparaginase Erwinia chrysanthemi | Protein / enzyme biologic | 25 mg/m2 | Intravenous |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Tofacitinib | Small molecule | 10 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
Indications
No indication recorded.